Navigation Links
VetStem Biopharma, Inc., Announces the Opening of its GMP Cell Therapy Manufacturing Facility
Date:2/21/2017

VetStem Biopharma, Inc., announced the opening of its GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, California. Based upon 12 years of knowledge gained by following GTP laboratory guidelines and utilizing the experience of both in-house personnel and consultants, VetStem constructed and validated a state-of-the-art GMP stem cell manufacturing plant. This clean room facility has already produced three registration batches of stem cell product and those batches have been officially released for use in pivotal FDA studies of safety and efficacy.    

Carolyn Wrightson, Ph.D., VP of Operations, stated, “This facility is the culmination of six years of planning and research, supported by over 12 years of commercial stem cell laboratory operations by VetStem’s experienced cell therapy team. We believe this is the first dedicated veterinary-specific cell therapy facility in the United States. It will provide all the stem cell products for use in VetStem FDA product development programs.” The facility operates under FDA GMP guidelines and is designed to produce commercial products, once approved by the FDA.

“Quality is a critical element necessary to bring stem cell therapy into mainstream veterinary practice. VetStem has been committed to quality since its founding and has worked directly with the FDA Center for Veterinary Medicine since 2003 to assure our products and services adhere to the strictest guidelines for safety and efficacy,” said Bob Harman, DVM, MPVM, CEO of VetStem. “VetStem offers tours of this unique facility via large viewing windows in an exterior corridor and veterinarians are amazed at the high tech approach to veterinary cell therapy including the specialized approach to donor selection, disease screening, clean room cell culture and final packaging of the product in specialized cell product vials.”

“Stem cell therapy is a truly novel and natural approach to treatment of acute and chronic diseases in animals that have few or less efficacious therapeutic options. Using donor derived allogeneic stem cells provides cell therapy in a “ready to use” format without the need for tissue collection, or processing thus expanding the availability to more animals. VetStem is dedicated to providing affordable stem cell therapy for diseases of dogs, cats and horses, especially in areas of unmet needs,” according to Harman.

About VetStem Biopharma

VetStem Biopharma is a veterinarian-lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 14 years and 12,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission is “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases.” In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 70 issued patents in the field of regenerative medicine.

Read the full story at http://www.prweb.com/releases/2017/02/prweb14079977.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. VetStem Biopharma, Inc. Will Present Data on Two Clinical Conditions and an Industry Overview at the North American Veterinary Regenerative Medicine Association Conference
2. VetStem Biopharma Acquires 24 New Adipose Stem Cell Patents
3. VetStem Biopharma Proudly Announces Dr. Mark Hughes as the Senior Manager, Veterinary Clinical Research and Safety
4. VetStem Biopharma is Pleased to Share the Success Story of Koda Who was Treated at Advanced Care Veterinary Services with Stem Cell Therapy.
5. VetStem Biopharma Regenerative Cell Therapy Has Been Used on over 12,000 Animals
6. VetStem Biopharma is Pleased to Share the Success Story of Lady Who Was Treated at Aloha Pet and Bird Hospital with Stem Cell Therapy
7. VetStem Biopharma is Happy to Announce Several of its Veterinary Clients have Surpassed the Centennial Mark by Performing VetStem Cell Therapy on over 100 Patients.
8. VetStem Biopharma Shares News of the Successful Treatment of a Non-healing Chronic Wound and Rear Leg Lameness, with the New Pall V-PET™ Platelet Therapy System
9. VetStem Biopharma Announces OC Mobile Surgery now offers Stem Cell therapy for dogs and cats suffering from orthopedic conditions
10. New Book Out with Two Chapters on Veterinary Regenerative Medicine Written by Dr. Bob Harman, CEO for VetStem Biopharma, Now Available through Amazon
11. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to Speak at the International Canine Sports Medicine Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2019)... ... September 17, 2019 , ... Catalent, a ... and Clinical Supplies Management, Asia Pacific (APAC) will present at the upcoming 3rd ... Sept. 25-26, 2019. , On Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney ...
(Date:9/17/2019)... (PRWEB) , ... September 16, 2019 , ... When a ... and kits that allow for the complete 3D characterization of tissues through the use ... transitioned into an imaging, image analysis and advanced cell culture focused contract research organization ...
(Date:9/11/2019)... ... September 09, 2019 , ... ... trial randomization and drug supply chain management, today announced its new technology partnership ... sciences industry. , “The integration between Veeva Vault EDC and our IRT will ...
(Date:9/8/2019)... ... September 04, 2019 , ... The Blavatnik Family ... the three Winners and six Finalists of the 2019 Blavatnik Regional Awards ... New York, New Jersey, and Connecticut since 2007, the Blavatnik Regional Awards recognize ...
Breaking Biology Technology:
(Date:10/3/2019)... ... October 02, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a ... FDA approved clinical trial for stem cell treatment of knee osteoarthritis . The successful ... as a subsidiary of VetStem Biopharma. , PSC CEO, Michael Dale, stated, “We are ...
(Date:9/30/2019)... ... ... As human induced pluripotent stem cells (hiPSCs) move closer to becoming a ... the human heart, there is an increasing need for stable stem cell lines that ... and easily recorded. A study released today in STEM CELLS details the development of ...
(Date:9/25/2019)... ... September 25, 2019 , ... Modality ... ranked No. 3094 on Inc. Magazine’s annual Inc. 5000 list, the most prestigious ... of 120 percent. Based on this growth, the Houston-based firm also ranked No. ...
Breaking Biology News(10 mins):